NSCLC
Conditions
Keywords
Elderly Patient
Brief summary
Immune checkpoint inhibitors(ICIs) combined with angiogenesis inhibitors may is synergistic in elderly patients with advanced non-small cell lung cancer(NSCLC), however its true efficacy is still unclear. The investigators retrospectively compared clinical efficacy and safety of driver-negative elderly patients with advanced NSCLC treated with ICIs with(or without)angiogenesis inhibitors in the Cancer Center of the Affiliated Suzhou Hospital of Nanjing Medical University.
Detailed description
The investigators reviewed the medical records of all lung cancer patients in the Cancer Diagnosis and Treatment Center of Suzhou Hospital Affiliated to Nanjing Medical University from January 1, 2019 to December 31, 2021, and a total of 79 patients were enrolled. The subjects were divided into two groups: the group treated with immune checkpoint inhibitors plus antiangiogenic drugs(IA group) and the group treated with immune checkpoint inhibitors without antiangiogenic drugs(NIA group). The data of PFS, OS, ORR, covariates, and Immune-related adverse events (irAEs) were collected through electronic medical records and follow-up. The primary endpoint of the study was PFS, and the secondary endpoints were OS, ORR and irAEs.All enrolled patients were followed up until August 1, 2022.
Interventions
DRUGImmune checkpoint inhibitors plus angiogenesis inhibitors
PD-(L)1-based therapy plus Bevacizumab or Anlotinib
DRUGImmune checkpoint inhibitors without angiogenesis inhibitors
PD-(L)1-based therapy
Sponsors
Suzhou Municipal Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥65 years old. 2. Stage IV according to the AJCC Cancer grading manual (8th edition). 3. Histologically confirmed NSCLC. 4. No driver mutations. 5. Received at least 2 courses of immunotherapy. 6. Expected survival time \> 3 months. 7. No concurrent malignancy. 8. Not participating in a clinical trial. 9. The functions of important organs were basically normal. 10. Sign informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | Up to August 1, 2022 | PFS was defined as the time from the start of the first immunotherapy until disease progression or death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | Up to August 1, 2022 | OS was defined as the time from the start of the first immunotherapy to death from any cause |
| ORR | Up to August 1, 2022 | ORR refers to the sum of complete response and partial response to treatment |
| irAEs | Up to August 1, 2022 | Immune-related adverse events were evaluated according to the CTCAE5.0 criteria |
Countries
China
Outcome results
None listed